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Abstract Protein therapeutics hold a prominent and rapidly expanding place among medicinal
products. Purified blood products, recombinant cytokines, growth factors, enzyme replacement
factors, monoclonal antibodies, fusion proteins, and chimeric fusion proteins are all examples of
therapeutic proteins that have been developed in the past few decades and approved for use in
the treatment of human disease. Despite early belief that the fully human nature of these
proteins would represent a significant advantage, adverse effects associated with immune
responses to some biologic therapies have become a topic of some concern. As a result, drug
developers are devising strategies to assess immune responses to protein therapeutics during
both the preclinical and the clinical phases of development. While there are many factors that
contribute to protein immunogenicity, T cell- (thymus-) dependent (Td) responses appear to
play a critical role in the development of antibody responses to biologic therapeutics. A range
of methodologies to predict and measure Td immune responses to protein drugs has been
developed. This review will focus on the Td contribution to immunogenicity, summarizing
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lymph node; ORG, unmodified original epitopes; FPX, recombinant Fc fusion protein; SFC, spot-forming cells.
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current approaches for the prediction and measurement of T cell-dependent immune responses
to protein biologics, discussing the advantages and limitations of these technologies, and
suggesting a practical approach for assessing and mitigating Td immunogenicity.
© 2013 The Authors. Published by Elsevier Inc. All rights reserved.
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1. Introduction
1.1. The immunogenicity of protein therapeutics
Since the approval of the first recombinant biological thera-
peutic, insulin, in October 1982, more than 165 biotherapeutic
agents have entered the marketplace and have generated an
estimated $99 billion in sales worldwide [1–4]. Therapeutic
biologics offer the advantages of increased specificity and
reduced toxicity compared to small molecules. However, when
administered to patients, these protein-based drugs have the
potential to elicit immune responses that may directly impact
drug safety, efficacy, and potency. For example, anti-drug
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antibodies (ADA) that develop in response to a therapeutic
protein may alter the drug's pharmacokinetic profile and
abrogate its pharmacodynamic effect (neutralizing activity)
[5–8].
Immune responses to proteins are characterized by the
generation of antibodies (humoral immune response) that
could be T cell dependent or independent. T-independent
antibody responses may be generated when B cells recognize
a repeated pattern (motif) in the therapeutic protein and
respond by transiently producing low-affinity, predominate-
ly IgM antibodies [9]. Antibodies that are generated in
conjunction with T cell help are referred to as T cell-
dependent or thymus-dependent (Td) antibodies. This
process, described in the next section, involves a complex
interplay among antigen presenting cells, T cells, secreted
cytokines, and B cells, emphasizing the importance of
genetic factors such as HLA haplotype expression and T
cell/B cell repertoire in immune responses to administered
proteins. Thus, measurement of ADA IgG responses usually
indicates that T cells are involved in the immune response to
the protein. Moreover, a number of clinical studies now
suggest that high levels of T cell-driven IgG ADA have the
potential to cross-react with the endogenous counterpart,
an adverse effect that can have serious consequences
[10–12].
T cell responses contribute to the generation of ADA.
Proteins with therapeutic potential are produced in cell lines
that are derived from a variety of sources, including
mammals (both human and non-human), insects, bacteria,
plants, yeast, and viruses. Small differences in the protein
sequence and/or post-translational modifications (e.g.,
glycosylation, oxidation, deamidation, acylation, and alkyl-
ation) can contribute to the immunogenic potential of the
therapeutic protein. Furthermore, the manufacturing pro-
cess may involve multiple steps (e.g., regulation of gene
expression, purification, concentration, formulation, and
long-term stabilization) to produce recombinant proteins of
sufficient quantity and quality to meet clinical release
criteria. At each of these steps, there is potential for the
introduction of biochemical or biophysical modifications into
the molecules that may influence the immunogenicity
profile of the biologic product. While these aspects of
protein production may not impact function of the thera-
peutic protein, modifications inherent in the manufacturing
process can have a major impact on host immune responses.
For example, consider the case of Erbitux, a protein with
non-human type glycosylations that caused anaphylaxis in
selected patients who had pre-existing antibodies targeting
these carbohydrate structures [13,14]. Host cell proteins
derived from recombinant protein-producing cell lines may
co-purify with a therapeutic product to become part of the
final formulation [15,16]. These impurities, even in small
quantities, have the potential to stimulate an unwanted
immune response. In at least one recent case, they induced
anti-host cell protein antibodies and contributed to the
suspension of a clinical trial [15,16].
So as to provide biologics developers with a structured
approach to measuring immunogenicity risk, the European
Medicines Agency (EMA) has published a “Guideline on
Immunogenicity Assessment of Biotechnology-Derived Ther-
apeutic Proteins” [17], in which factors influencing the
immunogenicity of therapeutic proteins were classified
into patient-, disease-, or product-related categories. The
patient- and disease-related categories describe factors
that may pre-dispose a particular individual to an immune
response. In contrast, product-related factors, i.e. factors
intrinsic to the final drug product itself that contribute
to immunogenicity, may include modifications in the
glycosylation profile [18–20], biophysical and biochemical
attributes [21–24], or factors introduced during formulation
[14,20,25,26]. Table 1 summarizes some of these patient-,
disease-, and product-related factors that have the poten-
tial to influence immune responses to a biologic therapeutic.
Many of the factors described in Table 1 that might
predispose a therapeutic protein to be immunogenic have
also been identified as “critical quality attributes” in the
FDA-sponsored Quality-by-Design initiative [27] focused on
manufacturing “process development”. For protein-based
drugs, the primary amino acid sequence itself can be a
strong determinant of immunogenic potential. Unfortunate-
ly, primary sequence is difficult, if not impossible, to modify
in the manufacturing process.
Although many protein drugs are associated with ADA, as
mentioned above, only a few have been associated with
severe adverse events such as profound anemia or thrombo-
cytopenia when the antibodies cross-reacted with the drug's
endogenous counterparts [10,11,28]. These types of serious
outcomes resulting from cross-reactive ADA have inspired
the development of a multitude of in vitro methods for
measuring the presence of ADA, which have been carefully
reviewed in several white papers and regulatory guidance
documents [17,22,29–33]. In addition, methods for identi-
fying drivers of Td immune responses have also expanded
and have been described in a number of publications
[34–42].
The goal of this paper is to review recent developments in
the understanding and identification of Td immune response
Table 1 Factors that can influence immune responses to a
therapeutic protein.
FACTORS IMPLICATIONS
Intrinsic immunogenic dominant epitopes
Sequence differences between therapeutic
protein and endogenous protein
– Aggregation
– Oxidation
– Deamidation and degradation
– Conformational changes
Route of delivery
–
–
–
– Differences in antigen presentation
following intravenous and subcutaneous
delivery
– Presence of leachates from syringe (i.e.
tungsten or silicone) can facilitate immune
responses
– Exposure to high dose proteins in
formulations can lead to an immune
response
Patient–related factors
–
–
–
•
•
• Age
–
–
Host Cell Proteins (HCP)
The homology of HCP with human proteins
raises concern over the inherent risk of
anti–self immune responses.
Cross–reactive neutralizing antibodies
to endogenous proteins
Breaking of tolerance due to
Route/frequency of administration
Syringe environment and associated
reconstitution
Non–physiologic concentrations
Immune status
Immunosuppression due to
supportive therapies
Autoimmune–diseased state
Genetic features like HLA
haplotypes
Intensity of treatment at the first dose
Recombinant protein therapeutics produced
in mammalian cell lines may contain
process–related contaminants.
Higher risk of immunogenicity based on
reactivity to HLA (DR, DP, DQ) alleles
Differences in glycosylation patterns. Structural
alterations induced by storage condition,
production/purification and formulation
Immune status can enhance or reduce
the likelihood of an immune response
Presence of HLA alleles that have high
potential to bind to immune dominant
epitopes
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drivers, and to organize these into a framework to approach
the prediction and measurement of Td immune responses as
one component of a risk assessment strategy. Case studies
will be presented to illustrate Td immunogenicity and the
practical application of these methods. An evidence-based
roadmap is proposed for identifying Td responses in protein
therapeutics and developing criteria for assessing immuno-
genicity by (i) sequence-driven assessment using in silico
algorithms, (ii) in vitro assays, and (iii) in vivo models.
Lastly, we touch on the emergence of methods for mitigating
Td immunogenicity, such as de-immunization and tolerance
induction.
2. The central role of T cells in immunogenicity
2.1. The T cell contribution to antibody responses
Immune responses to therapeutic proteins can be broadly
divided into two general categories. The first involves
activation of the classic adaptive immune system by what
are considered to be “foreign” proteins, like the response
elicited against pathogens, vaccines, or allotypic antigens.
Replacement proteins would be viewed as foreign to the
immune system of an individual who is lacking, in whole or in
part, the endogenous counterpart. The second involves a
breach of B and/or T cell tolerance, like the response
elicited to autologous self-proteins in certain autoimmune
diseases. The mechanisms for the breach of immune
tolerance are not as well defined as the mechanisms for
immune induction to microbial infections, but may include
epitope mimicry, cross-reactivity of T cells, presence of
trace levels of innate immune activators such as toll-like
receptor agonists [25,43,44], and/or multivalency as might
be presented by aggregated proteins [45].
For the classic immune pathway, production of anti-
therapeutic protein responses is the culmination of a series
of events that eventually leads to B cell activation and
antibody secretion. This antibody production can be thymus
independent [T-cell independent, (Ti)] or Td in origin
[46,47]. B cells are activated in a Ti manner when particular
structural patterns, such as polymeric repeats or carbohy-
drate molecules, directly induce activation of B cells. Ti
activation of B cells can be distinguished from Td activation,
as the antibodies resulting from Ti activation are limited in
both isotype and affinity and if memory B cells are generated
they are not long-lived [48,49]. In contrast, Td activation of
B cells is characterized by class switching (IgM to IgG) and
development of memory B cells that produce higher-affinity,
more robust, and longer-lived antibody responses. The
development of IgG-class antibodies following administra-
tion of a biological protein generally indicates that the
therapeutic is driving a Td immune response.
Td responses, by definition, are contingent upon T cell
recognition of therapeutic protein-derived epitopes through
the basic processes of protein antigen processing and
presentation. The therapeutic protein is taken up by
antigen-presenting cells (APC) and proteolytically processed
into small peptides. Certain of these peptides will bind to
human leukocyte antigen (HLA)/major histocompatibility
complex (MHC) class II molecules, where interactions of
sufficiently high stability with MHC will facilitate presenta-
tion of the peptide/MHC complex on the APC cell surface3
[50]. Because human populations express a number of
different HLA class II alleles, the interaction between
antigenic epitope and HLA may exhibit a full spectrum of
binding stabilities. HLA polymorphism and its impact on the
binding of specific peptides (HLA restriction) are primary
mechanisms by which patient genetics contributes to
immune responses to particular protein therapeutics. Exam-
ples of HLA-associated immune responses to therapeutic
proteins are provided below.
CD4+ T cell recognition of a specific antigen-MHC class II
complex, combined with co-stimulatory signals delivered by
the APC, culminates in robust T cell activation that in turn
facilitates a mature antibody response. In the absence of
activated T helper cells, naïve B cells do not fully mature,
and activated antigen-specific B cells are rendered anergic
or undergo apoptosis. Therefore, T cell recognition of
peptide epitopes derived from a protein therapeutic is the
key determinant of Td antibody formation.
2.2. T cell epitope stability and immunogenicity
Immunogenicity prediction is based on well-defined interac-
tions between the amino acids comprising a protein
sequence and an individual's HLA molecules. Setting aside
the influence of T cell receptor (TCR) affinity, the greater
the stability of a given peptide within the binding groove of a
particular HLA class II molecule, the greater the likelihood
that this peptide will elicit a T cell response [50]. Thus, the
identification of peptide sequences in a biologic drug that
bind to HLA is highly relevant for achieving the goal of
screening for immunogenic potential.
The presence of HLA-binding sequences in a protein
therapeutic is part of the larger biological process of antigen
presentation, T cell receptor (TCR) recognition, and T cell
activation, and thus is not an absolute guarantee that T cell
responses will occur. As elegantly described by others,
peptide processing and abundance, intracellular editing and
MHC loading by the DM protein, peptide–MHC stability, TCR
specificity and abundance, phenotype of the responding T
cell, and presence or absence of secondary signals all
contribute to initiating and shaping the quality and quantity
of a T cell response [18,20,25,26,50]. While the detection of
a T cell response to a putative epitope is an important
predictor of immunogenic potential, it has been much more
difficult to reliably model the intricate yet critical steps that
occur between the HLA binding event and the activation of T
cell response. Furthermore, the important contribution of
regulatory T cells (Treg), which may proliferate and produce
inhibitory signals in response to particular T cell epitopes,
has gained appreciation in recent years. Methods for
detecting and discriminating between regulatory and helper
T cell responses (Treg and T helper, respectively) are
discussed in greater detail below. Quite a few clinical trials
of protein therapeutics have now linked the presence of T
helper responses to immunogenicity, confirming the direct
3 The terms HLA (human) and MHC (encompasses both human and
mouse) are used interchangeably in this manuscript.
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relationship between T cell epitopes and the immunogenic-
ity of biologics [6,39,51–54].
2.3. Td immunity to therapeutic proteins
A classic T cell and Td antibody response to a therapeutic
protein antigen can occur after one or two administrations
of a particular protein therapeutic, persist for prolonged
periods of time, and ultimately inhibit the efficacy of the
therapeutic product. A classic Td immune response to a
protein therapeutic is illustrated by the induction of ADA
“inhibitors” in response to blood replacement factor VIII
(FVIII) in hemophilia patients. Although the incidence and
intensity of the immune response to FVIII can vary depending
on the extent to which endogenous FVIII is expressed in the
individual patient, immune responses to FVIII are driven by T
cell epitopes [55]. The differential between effector and
regulatory T cell immune responses to FVIII epitopes, on the
individual level, may be a factor that determines whether
that individual develops anti-FVIII ADA [56].
2.4. The role of central and peripheral tolerance to
biologics
The absence of an immune response to autologous proteins is
attributed to central (thymus-derived) immune tolerance to
proteins present in the respective individual's proteome.
According to the theory of central tolerance, T cells that
respond to epitopes derived from autologous proteins
expressed in the thymus undergo deletion or are rendered
anergic during thymic development [57]. Nonetheless,
tolerance to autologous proteins is now known to be
incomplete, since autoreactive T cells to self-antigens have
been uncovered in peripheral circulation in the context of
autoimmunity and are also present in the circulation of
healthy individuals. Natural regulatory T cells (nTregs) are T
cells generated in the thymus that circulate in the
periphery. Upon antigen-specific activation through their
TCR, CD4+CD25+FoxP3+ nTregs are able to suppress bystand-
er effector T cell responses to unrelated antigens by
contact-dependent and -independent mechanisms [58,59].
nTregs may hold immune responses to some autologous
proteins (such as erythropoietin) in check.
Adaptive Tregs, developed in reaction to foreign antigens
to which central tolerance may not exist, are an additional
source of control over immune responses [60]. Sustained
tolerance (to exogenous proteins) may require the existence
of these ‘adaptive’ or ‘induced’ Treg cells (aTreg, also
known as iTreg, [58]) with the same antigen specificity as
the self-reactive effector T cells [58,61–63]. Administration
of antigen in the absence of an innate-immune stimulator
(danger signal) can lead to tolerance; this approach has been
used for the induction of tolerance to allergens. A strong link
connecting HLA, presentation of T cell epitopes (both
regulatory and effector) in the context of HLA, and the
maintenance of peripheral tolerance has been described
[64]. The implications of immune control by nTregs and the
induction of tolerance via aTregs will be discussed in greater
detail below.
3. Methods for predicting Td immune responses
Detailed knowledge of the regions of localized immunoge-
nicity within the protein sequence may facilitate immuno-
genicity mitigation efforts. Here we begin with a review of
immunogenicity prediction methods, followed by a brief
description of strategies that may mitigate Td immunoge-
nicity including tolerization, deimmunization, and the
coadministration of the drug with immunosuppressive
therapies such as methotrexate, prednisone, cyclophospha-
mide, or Rituxan [65–68].
Predictive immunogenicity screening often involves more
than one approach, as each method has strengths and
weaknesses. A first step in the process may be to screen a
protein for the presence of T cell epitopes by sequence
analysis in silico. This step can be followed by in vitro studies
using a variety of methodologies, including HLA binding
assays, naïve blood assays, or humanized mouse models (see
below for descriptions of these assays).
3.1. In silico T cell epitope-screening methods
The core residues of the T cell epitope sequence that mainly
define the affinity and stability of binding to HLA pockets are
limited in length to 9–10 amino acids; thus prediction of T cell
epitopes based on the amino acid sequence of a peptide is
computationally feasible when sufficient information on a set of
peptides that are known to bind to a particular MHC is available.
Databases such as the Immune Epitope Database Analysis
Resource (IEDB; www.tools.immunoepitope.org) [69] provide
the raw material for developing T cell epitope prediction tools.
Presentation of epitopes by both MHC I and MHC II
contributes to the initiation of an immune response. MHC II
is more relevant to anti-drug antibody responses, as MHC
Class II-restricted T helper cells are responsible for driving
humoral immunity. HLA DR, DQ, and DP are the three loci
of peptide-carrying HLA class II molecules. In vitro and
in vivo observations indicate that HLA DR binding peptides
are generally 12 amino acids in length, as the flanking
sequences serve to stabilize the peptide (by hydrogen
bonds) in the HLA binding groove [70]. Systematic assess-
ments of MHC class II peptide binding domains of proteins
have been developed using machine learning methods,
software algorithms, and data transformations [71–73].
For a brief overview of T cell epitope mapping tools, see
Table 2 [69,74–80]. A common denominator among these
tools is the ability to quickly screen large datasets,
including whole genomes or proteomes, for putative T cell
epitopes. Several common HLA-DR types share HLA binding
pocket repertoires [81], meaning their ability to bind
peptides is more promiscuous than for class I alleles.
Moreover, analysis focused on as few as eight representa-
tives of the 875 known HLA-DR alleles can “cover” the
genetic backgrounds of most humans worldwide [82].
Additionally, MHC class II-binding T cell epitopes have been
observed to occur in clusters of up to 25 amino acids in length
[72,83]. Thus identifying MHC class II-binding T cell epitope
clusters can be a strong indication for T cell responses because
they represent regions of the protein in which sequences that
have high affinity across multiple HLA alleles and multiple
frames are located [79].
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It is notable that there are few examples in the literature
of an association between HLA-DP or -DQ and immunogenic-
ity. This may be due to the fact that binding motifs of
HLA-DP and HLA-DQ alleles are less well defined than
HLA-DR alleles, and/or that HLA-DP and HLA-DQ may
contribute very little to drug-related immunogenicity. A
recent retrospective analysis of previously published immu-
nogenicity prediction data [72] found no association be-
tween the presence of DP or DQ motifs (as predicted using
online tools accessible through the IEDB) and immunogenic-
ity of 23 monoclonal antibodies that have been evaluated in
human clinical trials [199].
The computational approach to MHC class II T helper cell
epitope prediction and its application to Td immunogenicity
assessment has been described in previous publications
[84–90] and is now well accepted in vaccine discovery
efforts [85,91–94] and for the identification of key epitopes
triggering autoimmunity [95]. In the context of biologics,
several studies of therapeutic proteins mentioned above
[6,51] have demonstrated the prospective predictive accu-
racy of these algorithms by showing a positive correlation
between the presence of an MHC binding sequence and
observed Td immunogenicity in the clinic (demonstrated for
a recombinant fusion protein, FPX, in Table 3). A specific
example is provided in detail in the case studies section of
this article. Some groups have also developed tools that are
expressly designed to rank therapeutic proteins by T cell
epitope content [72] and to define means of modifying
epitope content in silico [35,96,97]. Application of in silico
tools reduces downstream in vitro testing dramatically,
typically by at least 20-fold [98], and provides an opportu-
nity in early development to modify a protein to decrease its
immunogenic potential.
3.2. Strengths and limitations of in silico analysis
3.2.1. Antigen processing
In vivo, immunologically relevant epitopes are produced by
the APC, which processes the protein into discrete peptide
fragments, assembles the peptides in complexes with MHC
molecules, and displays these complexes on its cell surface
[99,100]. The non-classical MHC class II molecule HLA-DM
acts as a T cell epitope editor, reducing the number of
epitopes that are eventually presented at the APC surface
through kinetic proofreading [101]. Methods that will
predict products of antigen processing and contribute to
the accuracy of Td immunogenicity assessments are under
development [50,102,103]. One means to qualitative-
ly identify the peptide sequence of epitopes that are
presented following HLA-binding and DM-editing is to
directly elute naturally processed HLA-associated peptides,
followed by peptide sequencing [103–105].
3.2.2. MHC affinity
A prerequisite for T cell epitope immunogenicity is the
stable binding of a linear epitope in the groove of the MHC
molecule; the higher the kinetic stability (slow peptide
off-rate), the longer it will reside within the MHC cleft, and
the greater the likelihood that an epitope will be recognized
by a T cell [106]. Improved prediction of peptide–MHC
Table 2 Summary of T cell epitope mapping tools, in alphabetical order.
NAME DEVELOPERS/INSTITUTION TYPE WEBSITE
Epibase I. Lasters and P. Stas
Algonomics NV/Lonza, Inc.
Commercial www.lonza.com
EpiMatrix A.S. De Groot and W.D. Martin
EpiVax, Inc.
Collaborative/Commercial www.epivax.com
IEDB Vita R, Zarebski L, Greenbaum JA, Emami H, Hoof I,
Salimi N, Damle R, Sette A, Peters B. The immune epitope
database 2.0. Nucleic Acids Res. 2010 Jan;38:D854-62.
Mixed collection of
tools of assorted derivation
www.iedb.com
MHC2PRED G.P.S. Raghava
Bioinformatics Center, Institute of Microbial Technology,
Chandigarh, India
Public www.imtech.res.in/raghava/mhc2pred/
MHCPRED D.R. Flower
The Jenner Institute
Public www.ddg-pharmfac.net/mhcpred/MHCPred/
PROPRED/
TEPITOPE
G.P.S. Raghava and H. Singh
Bioinformatics Center, Institute of Microbial Technology,
Chandigarh, India
Public www.imtech.res.in/raghava/propred/
RANKPEP P.A. Reche
Harvard Medical School
Public http://bio.dfci.harvard.edu/RANKPEP/
SVRMHC P. Donnes, A. Elofsson
Division for Simulation of Biological Systems, University of
Tubingen, Germany
Public http://svrmhc.biolead.org/
SYFPEITHI H.G. Rammensee
Department of Immunology, Tubingen, Germany
Public http://www.syfpeithi.de
SMM-Align/
NetMHCII-2.2
M. Nielsen, C.Lundegaard, and O. Lund
Center for Biological Sequence Analysis, Department of
Systems Biology, Technical University of Denmark
Public www.cbs.dtu.dk/services/NetMHCII-2.2/
TCED/iTope M. Baker and F. Carr
Antitope, Ltd.
Commercial www.antitope.co.uk/
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stability might improve the ability of in silico methods to
predict activation of CD4+ T cells in vivo [106]. While in silico
tools have dramatically improved over time, and consider-
ation of epitope “off-rate” or peptide “residence time” on
the MHC molecule is probably within reach of future
generations of algorithms, in contrast, TCR affinity is
unlikely to be amenable to in silico prediction, as the TCR
is pleiomorphic and exhibits three-dimensional complexity
akin to B cell epitopes.
3.2.3. T cell phenotype
Identification of T cell epitopes in a protein may indicate
that the protein could induce an immune response, though
the nature of the response remains heavily dependent on the
phenotype of the T cell that recognizes this epitope in the
context of MHC class II and on the local milieu (inflammatory
or regulatory). The prediction of the type of T cell (T helper,
T regulatory, etc.) responding to a potential T cell epitope
remains beyond the capabilities of the in silico approaches
described here: phenotyping requires in vitro characteriza-
tion, except in cases where known regulatory T cell epitopes
have been previously described.
3.2.4. Individual versus population-level predictions
Caution is advised when applying T cell epitope prediction
tools that have been developed for the purpose of predicting
immune responses in large populations to an individual
subject. As HLA binding is intimately associated with T cell
response, individual responses to protein therapeutics will
vary depending on multiple factors, such as an individual's
HLA haplotype [53,89] and immune status. Individual T cell
repertoire variation further complicates the interpretation
of individual subject responses; current thinking is that a T
cell repertoire is defined by previous exposures to related
epitopes, vaccination, and the internal (gut) microbiome
[107,108]. Such individual specificity, in addition to antigen
processing (see above), may explain why some MHC binding
peptide sequences do not induce T cell activation [109].
Thus, Td immunogenicity on the population level, as
predicted by tools that measure the potential for immuno-
genicity across HLA alleles, can be quite different from
immunogenicity at the individual level. In silico tools can be
used to predict the former in the pre-clinical phase of
development; the same tools may be useful to analyze
subject-by-subject immune responses to a protein thera-
peutic in the clinical phase of development.
3.2.5. Post-translational factors
Additional determinants of Td immunogenicity that are not
considered in the in silico prediction process may be
revealed in vitro. For example, effects of non-sequence-
derived post-translational modifications including those of a
biophysical or biochemical nature such as deimination (or
citrullination), deamidation, oxidation, dimerization, and
protein folding-induced conformational changes that are
all widely accepted as determinants of immunogenicity
[21,110].
Despite these caveats, T cell epitope prediction has
advanced greatly over the last decade. In silico tools provide
the advantages of high throughput, low cost, and the ability
to reduce the search space for further in vitro testing. In vivo
immunogenicity, however, is also influenced by a number of
factors that cannot yet be accurately predicted in silico
[71,80]. The results of in silico analyses can then be carried
to the next step of pre-clinical analysis, such as HLA binding,
antigen processing and presentation assays, and T cell
assays, in which other factors that contribute to generating
an immune response can be examined.
3.3. HLA binding assays
Having defined the regions of interest in silico, one means of
validating these predictions is to perform HLA/MHC binding
assays. A number of different HLA class II binding assays can
be used to measure the affinity of predicted epitope
sequences to HLA alleles in vitro; several are described in
this section.
3.3.1. Competition binding assays
One method that is employed is a competition-based HLA
binding assay, described previously [111–113] that can be
adapted for high throughput [114]. The method is described
in detail in other publications, but briefly, experimental
peptides are tested for their ability to compete against a
labeled high-affinity peptide for binding to purified class II
molecules. The reaction is carried out at several peptide
concentrations; a non-linear regression analysis of the
resulting dose–response curve is then used to calculate the
IC50 (concentration of test peptide required to compete off
50% of the target peptide). Binding assays can performed for
a broad representation of class II alleles [82]. One drawback
of this method is that measurements of peptide affinity are
always relative to this standard reference peptide, as
the appropriate reference peptide may differ from HLA
allele to allele. A value that describes the 50% inhibitory
concentration (IC50) can be derived by fine-tuning the
protocol for each allele through repeated experiments, and
performing the assays at multiple concentrations. IC50 values
Table 3 Association of algorithm-predicted immunogenicity
to clinical immunogenicity rates. EpiMatrix-generated scores
associated with each FPX protein and their respective rates of
antibody incidence (binding and neutralizing) are shown. An
assessment of Tregitope content in each molecule was also
performed and scores were adjusted accordingly. FPX 1, for
example, had a high rate of clinical immunogenicity and was
associated with elevated T-cell epitope content and low
Tregitope content, as reflected by its high Z score. FPX 2, 3,
and 4 were associated with a low EpiMatrix score, and
Tregitope adjustment further reduced the predicted poten-
tial for binding. Predictably, FPX 2, 3, and 4 exhibited only
minor clinical immunogenicity.
Protein Therapeutics FPX 1 FPX 2 FPX 3 FPX 4
EpiMatrix Score 21.97 1.76 —0.76 1.63
Tregitope — adjusted 
EpiMatrix score 21.97 1.62 —1.76 —111.25
Binding Antibodies 37% 7.80% 5.60% 4.50%
Neutralizing Antibodies 40% 0.50% Not Analyzed 0%
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can be converted to method-independent Ki values via the
Cheng–Prusoff equation for comparison of peptide affinities
across platforms [115].
3.3.2. Direct binding assays
It is also possible to measure peptide affinity directly, rather
than observing its ability to displace a known ligand. In such
experiments, a variety of methods may be used to separate
peptide bound to HLA molecules from free peptide in
solution, thus allowing for assessment of the peptide's
affinity. Spin-column filtration and gel electrophoresis are
ways to accomplish this distinction by molecular weight,
since peptide–HLA complexes will weigh more than unbound
peptides. These methods, however, are tedious and can
suffer from complex dissociation during the separation
process. Other novel methods have been proposed, such as
proximity-based detection utilizing a Luminescent Oxygen
Channeling Immunoassay [116]. All of these techniques allow
more direct binding affinity determination than competition
studies, but have methodological limitations and require
costly equipment.
3.3.3. Real-time kinetic measurements
Apart from determining the quantity of displaced reference
peptide (competition assay) or bound vs. free test peptide
(direct assay), the rate at which peptides interact with
HLA molecules is a dimension of epitope strength that can
be measured in vitro. Protocols based on fluorescence
polarization are suitable for kinetic studies due to the
absence of interference from ELISA wash steps, allowing
multiple readings to be taken throughout the binding
reaction [117]. Additionally, surface plasmon resonance
methods have also been employed to measure peptide
binding to MHC II [118].
3.4. Strengths and limitations of HLA binding assays
In vitro HLA binding assays are relatively straightforward and
easier to perform than live-cell experiments. However, each
of the assay formats can be affected by peptide purity and
length as described here. Peptides that are synthesized for
HLA binding assays must include carboxy- and amino-
terminal flanks that stabilize the peptide in the MHC groove
[119]. Selection of peptides based on artificially defined
overlapping sequences (e.g., 15mers overlapping by ten
amino acids) can lead to the truncation of MHC binding
motifs and elimination of critical flanking regions, which
limits the accuracy of the binding assay. Furthermore,
artificially synthesized peptides may contain impurities,
truncations, and errors in the sequence that can lower or
alter the binding of the pure peptides; thus high-quality
peptides (greater than 90% purity) are required to obtain
more accurate results in binding assays. Long peptides can
fold or peptides can aggregate in solution, leading to
underperformance in binding assays. Solvents used in the
experiment may interact negatively with certain amino
acids, causing oxidation or the formation of unwanted
disulfide bonds. Quality-controlled peptide manufacturing
and storage, along with proper reagent selection, can
minimize the impact of these problems [113,114].
While epitopes can be predicted (in silico) and validated
in binding assays (in vitro), the final impact of the T cell
epitope is through its activation of a T cell. Activation is
related to TCR specificity, avidity and T cell phenotype
(none of which are measured in HLA binding assays), which
makes straightforward interpretation of immunogenicity
based upon HLA binding assays impossible. Thus, HLA binding
assays may improve the accuracy of immunogenicity predic-
tions when applied in a step-wise process after in silico
epitope prediction and before the employment of a
biological assay such as enzyme-linked immunosorbent
spot-forming (ELISpot) assays or HLA transgenic mouse
studies, but additional assays that assess T cell responses
may need to be performed [120].
3.5. In vitro T cell assay methods for Td
immunogenicity analysis
For many years, in vitro assays based on HLA haplotype have
been used in transplantation research to assess the risk of
engrafted T cells responding to host tissue (graft-versus-host
disease). Adaptation of these assays to protein therapeutics
may improve the pre-clinical assessment of the potential for
Td immunogenicity. The presence of T cells that actively
suppress immune responses to autologous proteins is a
significant confounding factor in their development and
evaluation. In addition, these assays are dependent on the
selection of a culture milieu that accurately accounts for the
in vivo conditions of human immune stimulation [40,54,121].
In this respect, bulk cultures of PBMC, either with or without
co-stimulatory signals (anti-CD28 antibody, IL-2, IL-7, etc.),
have been utilized to assess immunogenicity of therapeutic
proteins.
A number of biological outcomes for T cell activation can
be measured in these in vitro assays, including cytokine
secretion (IFN-γ, IL-2, IL-4, etc.), regulation of cell surface
markers of activation, signal transduction events, and
proliferation [122,123]. Supported by such evidence, in
silico-identified peptides that stimulate multifunctional T
cell responses in vitro can be considered bona fide T cell
epitopes with the potential to contribute to an ADA
response.
3.5.1. Measurement of T cell cytokine responses
ELISAs and ELISpots are two related methods of measuring
cytokines secreted by T cells (i.e., IFN-γ, IL-2, IL-4, and
IL-10). The enzyme-linked immunosorbent assay (ELISA) can
measure cytokine levels in culture supernatants generated
under conditions of T cell stimulation. Cytokine levels
measured in an ELISA can provide information about the
magnitude of the response (how much cytokine is secreted
into the supernatant) as well as the type and quality of the
response (which cytokines are or are not secreted into the
supernatant). Multi-analyte, high throughput cytokine test-
ing can also be performed in cell-derived supernatants in
bead-based assays [124–127]. Enzyme-linked immunosor-
bent spot-forming (ELISpot) assays provide information
regarding the number of cytokine-producing cells (down to
1 cell per million) within a cell population stimulated ex
vivo; these assays are considered to be more sensitive and
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quantitative whereas ELISA and bead-based assays are
slightly less sensitive and more qualitative.
Intracellular cytokine staining measured by flow cytom-
etry is another method for detecting cytokines and linking
their expression to the phenotype of individual cells.
These assays can be used to accurately measure T cell
polyfunctionality relative to the phenotypic classifications
of CD4+ T cells based on cell surface markers.
3.5.2. T cell proliferation
T cell proliferation in response to stimulation by a peptide–
MHC complex can be measured by (1) the incorporation
of the radioactive nucleotide tritiated thymidine into the
DNA of dividing but not resting cells or (2) the dilution of
a fluorescent dye, carboxyfluorescein succinimidyl ester
(CFSE), that decreases in fluorescence intensity by half
with each round of cell division and can be measured by
flow cytometry. Thymidine incorporation assays are gradually
being replaced by CFSE staining, which presents significant
advantages in terms of ease-of-use. In addition to CFSE labeling,
cells can be co-stained for expression of other cell surface
markers, transcription factors, and/or intracellular cytokines
that distinguish between regulatory T cells and effector
T-helper cell phenotypes, including Th1, Th2, Th17, Th22,
etc. as reviewed in detail elsewhere [128–130].
3.5.3. Tetramers
Fluorescently labeled tetrameric complexes of MHC class II
molecules loaded with the peptide of interest (i.e., “tetra-
mers”) can also be used to enumerate T cells recognizing a
particular epitope. However, relative toMHC I tetramers, MHC
II tetramer staining has proven problematic and so their utility
has been restricted. The technical limitations experienced
specifically with MHC II tetramers may be due to weaker TCR–
peptide–MHC II interactions or the fact that CD4 does not
participate in the stability of tetramer binding as does CD8
[131]; either one or both of these features may contribute to
increased variability and poor quality of the experimental
output. Efforts continue to improve MHC II tetramer–TCR
interactions towards the goal of increasing the utility of MHC II
tetramers so that they may be more widely used for the
identification of specific CD4 T cell responses, including those
against protein therapeutics.
3.5.4. Naïve T cell in vitro assays
Naïve peripheral blood mononuclear cells (PBMC) have been
used to describe Td immunogenicity of therapeutic proteins
[34,40,132,133]. Compared to a recall response, the precursor
frequency of antigen-specific cells in a naïve population is
quite low; it was postulated that the higher the precursor
frequency reactive with a certain peptide or protein, the
higher the potential of the respective peptide or protein to
induce an immune response [134]. Multiple rounds of antigen
stimulation, sometimes over several weeks, are required to
expand sufficient numbers of antigen-specific T cells for
reliablemeasurement. By conditioning naïve blood samples ex
vivo through prolonged and/or repeated exposure to experi-
mental antigen, immune responses can be expanded to the
point where they can be measured. What is not known is how
expansion affects the phenotype of the T cell response; either
regulatory or effector responders may eventually dominate in
in vitro cultures.
3.5.5. T cell assays using whole antigens
T cell assays usingwhole antigens also can be used tomeasure T
cell responses to protein therapeutics in vitro. The recognition
of these antigens requires the presence of an APC that is
capable of processing and presenting peptides derived from the
antigen. Advantages of whole PBMC assays include the ability
to set up several assays and/or assay conditions with a limited
blood sample volume and the ease of assay performance,
features which lend themselves to high-throughput assay
development [40]. Human monocyte-derived dendritic cells
can be manipulated in vitro to model antigen processing by
professional APC in vivo (H. Kropshofer, unpublished data).
However, as applied to evaluating immunogenicity of biologics,
optimization of variables such as the ratio of DCs to autologous
T cells are important factors for ensuring that the in vitro
results are relevant to the clinical scenario.
3.5.6. T cell re-stimulation assays using “exposed” donors
T cells re-stimulation assays are generally used to identify
and measure a recall or memory response in PBMC derived
from subjects who have been exposed at a distant time point
to a protein or a given biologic product. Whereas ‘exposed
blood’ assays cannot be performed for novel therapeutics,
this type of assay can be used to evaluate the impact of
pre-existing immune responses to a new version of an
existing biologic in use such as a re-engineered FVIII. Epitope
mapping of the recall response can be performed using
specific peptides from the whole protein; however, this
approach may be over-predictive. Therefore, studies using
whole therapeutic protein should ideally be performed in
parallel with studies using sets of predicted peptides.
Antigen-specific T cell responses can be assessed after
re-stimulation ex vivo by ELISA, ELISpot, proliferation, and
flow cytometric analysis of activation markers and intracel-
lular cytokine expression.
3.5.7. Reconstitution of T cell immune responses in vitro
New methods for “reconstituting T cell immune responses”
in artificial media may permit improved in vitro assess-
ments of the interactions between the professional APC and
the T cells. To this end, several artificial lymph node (ALN)
systems have been developed [135–137]. These methods
attempt to replicate, in three dimensional structures and in
APC:PBMC ratios, the natural immune environment [138]. In
at least one approach, human blood-derived dendritic cells
are cultured in transwells partitioned by human vascular
endothelial cells. Addition of autologous CD4+ T cells to the
co-culture allows activated APC expressing chemokine
receptors to respond to inflammatory chemokines and
migrate through the transwells, mimicking the migration
of APC from the periphery to the lymph nodes. The
antigen-specific CD4+ T cell response is monitored by
CD154, IFN-γ, IL-2, IL-5, IL-17, and IL-21 expression. A
good correlation between previously established immune
responses in vivo and ALN immunogenicity has been
observed, at least for protein-based vaccines [139]. Even
though the human ALN model is primarily being used for in
vitro evaluation of vaccine efficacy [140], the application of
this technology for the prediction of therapeutic protein
immunogenicity is feasible.
Alternatively, some groups have used small flow-through
systems that induce PBMC to self-assemble into lymph
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node-like structures [141]. Pre-activation of the T cells
improves the readouts; however, the introduction of
specialized (non-self) APC may generate false positives for
some biologic proteins. In other cases, these ALN systems
have given results that correlate with predicted immune
responses [135,142].
3.6. Strengths and limitations of in vitro T cell
assays for Td immunogenicity analysis
The benefit of in vitro T cell assays utilizing easily accessible
human peripheral blood is that the assays may provide a
preview of the immunogenicity of a therapeutic protein
without the risks typically associated with first-in-human
use. Careful consideration of the composition of the cells in
culture, such as monocyte-derived macrophages, immature/
mature dendritic cells, and T and B cells, may improve the
ability of a protein to initiate and propagate an immune
response. Furthermore, these assays incorporate antigen
processing and presentation pathways for whole proteins as
well as for discrete peptides.
A limitation of ELISpot and ELISA assays is that PBMC contain
several cell types capable of secreting particular cytokines,
e.g., IFN-γ (NK cells, NKT cells, CD4+ or CD8+ T cells). Thus
PBMC-based assays tomeasure cytokine production by a specific
lymphocyte subsetmay need to be fine-tuned such as by the use
of subset-depleted or subset-enriched PBMC preparations.
Another potential issue related to T cell assays is that the
concentration of whole protein or peptide in the cell culture
may need to be titrated relative to the number of T cells. The
optimal concentration of protein required for proper evaluation
of immune responses in vitro may be non-physiologic due to a
limited antigen-presenting population and/or co-stimulation. T
cell assays also require support with homeostatic cytokines
(IL-2, IL-7, IL-15, etc.) to reduce bystander effects [40]. In
addition, optimization of T cell concentrations may be
required [143].
While “irrelevant” cells secreting cytokines in vitro may
contribute to overestimation of the frequency of activated
T cells, their presence also contributes to the overall level
of activation of cells in the assay. Cells such as NK cells,
CD8+ T cells, and basophils may play a supportive role in
these cultures [144], thus their removal can modify the
outcome of a truly representative immune response.
Finding the right balance between minimization of irrele-
vant immune responses and support for the in vitro immune
response is one of the major obstacles to widespread
adaptation of in vitro T cell assays for pre-clinical screening
of protein therapeutics.
Viable and functional T cells are also required for the
assay; standardized and optimized procedures for handling
and storing whole blood are needed to ensure the accuracy
of subsequent assays. Furthermore, blood from naïve and
drug-exposed individuals can differ in the content of
antigen-specific T effector and T regulatory cells. Based on
the nature of response (in vivo primed vs. stimulated and
recalled), stimulation methods and the amount of antigen
required for challenge can also differ. Naïve cells will
require multiple in vitro stimulations to amplify detection,
while antigen-specific recall responses can be elicited even
with a single challenge.
Similarly, stimulation can be performed with peptides or
whole proteins alone, peptides in the context of tetramers,
or APC pulsed with whole proteins. New advances in
tetramer/multimer technology can enhance detection of
epitope-specific T cells and thus should allow more sensitive
and standardized approaches to evaluate individual re-
sponses to T cell epitopes identified in protein therapeutics
[145].
Finally, the number of individual blood (PBMC) donors
that would normally be required to address the HLA diversity
of a patient population is quite large (more than forty), and
the volume of blood required ranges from 15 mL to more
than 50 mL. Maintenance of a large supply of blood samples
from pre-qualified donors that is sufficient to reduce
assay-to-assay variation can be done, but is cost prohibitive
for most preclinical laboratories.
Much remains to be done to improve the accuracy of in vitro
T cell assays in predicting clinical immunogenicity. Future
considerations for improving in vitro T cell assays include:
better linkage between the spectrum of immune responses to a
therapeutic protein and predictive power in clinical trials
using statistically derived criteria, such as fold-increase or
stimulation-index; improved means to distinguish responders
from non-responders; evaluation of T cell responses from
diseased states associated with inflammation or immune
suppression; selection of the optimal set of markers for the
identification of activated T cells; and improved ability to
differentiate Treg and CD4+ Teff responses (one schema has
been offered by the HIPC consortium [146]). Additional
improvements require establishing clear parameters that define
memory versus naïve T cell populations, influence due to
bystander cells, and standard methods for PBMC harvest,
preparation, and storage. Concurrent with efforts to standard-
ize, in vitro immunogenicity screening assays are being
incorporated into the preclinical pipeline by a number of drug
developers.
3.7. Mouse models of in vivo Td immunogenicity of
human therapeutic proteins
Important advances in understanding MHC restriction, map-
ping of epitope recognition for murine epitopes presented by
murine MHC, and T cell function have been achieved with in
vivo mouse studies. However, when we turn to in vivo mouse
studies for prediction and validation of Td immunogenicity for
clinically relevant proteins, there are two major limitations
that must be taken into consideration. The first is that human
and murine proteins are not identical, thus administration of
protein therapeutics to mice may result in responses to
components of the protein that are foreign to mice; and
second, murine MHC will present mouse, not human, T cell
epitopes. Since murine models provide a means of evaluating
immunogenicity and an important bridge to the clinic, a
number of enhanced models have been developed.
3.7.1. HLA transgenic mice
The HLA transgenic lines are generated by incorporation of
specific human HLA genes into murine MHC class II-deficient
mice, producing a mouse strain that expresses human class II
HLA in the absence of mouse class II MHC [147,148]. Thus,
these mice process and present epitopes in the context of
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human HLA, and their T cells recognize epitopes presented by
human HLA. They aremost useful when directly comparing two
proteins that are very similar (such as FVIII and versions of FVIII
that have fewer epitopes or new glycosylations) [97]. A direct
correlation has been found between epitopes that elicit T cell
responses in infected humans and those that induce T cell
responses in immunized HLA transgenic mice [149–152].
HLA transgenic mice are now routinely used to test and
optimize (human) epitope-driven vaccines in preclinical
studies [153–155]. For example, Hanke et al. mapped HIV
epitopes in transgenicmice, and thenmoved their DNA vaccine
through abbreviated primate studies after proving that the one
non-human primate epitope engineered into the vaccine
stimulated T cells [156].
The formation of anti-FVIII antibodies, also known as
inhibitors, is a major obstacle to FVIII gene replacement
therapy in hemophilia A patients. After intravenous adminis-
tration of FVIII, the immune response mounted is dependent
on CD4+ T helper cells, as has been demonstrated by numerous
studies in mice and humans [157–162]. More currently,
interference with T–B cell interactions in hemophilic mice
was shown to reduce inhibitor formation [159,160,162].
An example of the use of HLA transgenic mice for evaluating
the application of immunogenicity prediction tools towards
the goal of deimmunizing a therapeutic protein was recently
published in Clinical Immunology [97]. In silico tools were
utilized to predict immunogenic peptides within the C2 domain
of FVIII. Changes to amino acids in positions predicted to be
important for binding to the HLA DR3 MHC class II pocket were
modified with the intent of disrupting peptide–MHC binding.
The same predictive tools were reapplied to assess the binding
potential of the modified peptides. This process was reiterated
until the predicted binding to HLA DR3 was reduced.
The de-novo immunogenicity of these modified peptides was
tested in hemophilic E16 mice (H-2b; [163]) and in HLA-DR3
transgenic mice [164]. The initial immunogenicity study
results, in which mice were immunized with the unmodified
original (ORG) epitopes predicted by in silico analysis of the C2
domain, were consistent with predicted responses for either
H-2b- or HLA-DR3-expressing mice. These two mouse strains
were crossed to produce E16xDR3 mice, in which an immune
response of intermediate magnitude was observed. Specifi-
cally, the immunogenicity of epitopes derived from FVIII in the
E16xDR3 mice was consistent with the absence of tolerance
induction to this sequence (the E16 mice do not express
full-length FVIII) and the presence of MHC (I-Ab) bindingmotifs
in the sequence [97]. In proliferation assays, modified epitope
peptides were less antigenic than ORG peptides. In general,
lower antigenicity was observed for those peptides that had
two rather than just one amino acid substitution. Similarly, in
terms of de novo immunogenicity, the more mutations, the
lower the observed proliferative response in general.
In addition to providing an example of how in silico
tools can be applied early in the development process to
mitigate immunogenicity risk, this study also highlights
certain limitations of available mouse models for risk
assessment. While certain epitopes are predicted to bind
promiscuously to both human HLA DR3 and I-Ab MHC, others
demonstrate greater restriction by either the human or the
mouse MHC. Thus the lack of observed immunogenicity may
be attributed to the absence of a relevant MHC expressed in
the mouse model.
With regard to theHLA DR transgenicmodels, those peptides
predicted to be HLA ligands were only immunogenic when the
sequence contained mismatches between the human FVIII
sequence used in the immunization and the corresponding
sequence in the native mouse FVIII protein [97]. To be
immunogenic, the mismatches had to occur within 9-mer
sequences that also contained HLA DR3 or DR4 binding motifs.
When presented to the mouse T cell, these 9-mers would
appear “foreign” and thus stimulate T cell proliferation.
Peptides that were predicted to bind HLA DR3 and/or DR4 but
did not stimulate immune responses were found to contain no
mouse/human sequence mismatches.
In summary, identification of T cell epitopes and
development of de-immunized versions by targeted se-
quence modification can lower HLA binding and proliferation
responses, but the process has the potential to impact
protein function
3.7.2. Humanized mouse models
“Humanized” mice engrafted with a functional human
immune system are now being used to study human
hematopoiesis, immunity, regeneration, stem cell function,
cancer, and human-specific infectious agents. Immunocom-
promised SCID/NOD/γ chain−/− or RAG2−/−/γ chain−/−
mice, utilized as recipients to facilitate acceptance of
human tissue, are engrafted with functional human hema-
topoietic stem cells (CD34+), liver, and thymus [165]. The
result is a cohort of mice in which human myeloid and
lymphoid lineages are reconstituted from a single human
donor, and the interactions of these cells in a complex
biological environment can be studied. XenoMouse® (de-
scribed below), in addition to the humanized mice such
as NOD/Shi-scid/IL-2Rγnull (NOG), NOD scid IL2 receptor
gamma chain knockout mice (NSG), bone marrow, liver,
thymus transplanted mouse (BLT), and bone marrow
transplanted mouse (BMT) have all been used as animal
models to evaluate human immune responses [165–168].
3.8. Strengths and limitations of mouse models of in
vivo Td immunogenicity
These evolving mouse models could provide functional and
testable elements of the innate and adaptive human immune
system without putting patients at risk [169]. The species
specificity of a number of cells and molecules critical for a
fully functional immune system remains a limitation in these
models. For example, in HLA transgenic mice, the T cell
repertoire will be shaped by epitopes derived from mouse
proteins presented by a single human HLA allele to mouse
TCR. This confounds the application of HLA transgenic mice
for determination of immunogenicity of a human protein
therapeutic. And while humanized (SCID/Hu) mouse models
are improving, certain aspects of a fully functional immune
response relevant to immunogenicity prediction and mitiga-
tion are lacking, such as the ability to elicit the complete
spectrum of B cell antibody responses or the ability to
proteolytically process antigens in a way that recapitulates
what has been observed for human endosomal/lysosomal
proteases.
The XenoMouse®model has been of particular interest, as it
is transgenic for nearly the complete human immunoglobulin
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locus, thus is tolerant for human IgG2/kλ antibodies, but is
deficient for mouse IgH and Igk chains. The human-like humoral
immune response in XenoMouse® is restricted by mouse MHC
and T cell help but is not as robust as in wild type mice,
potentially due to inefficient signal transduction and isotype
switching mediated by accessory factors that are necessary for
B cell maturation. Hence the utility of such a model to study
immune responses to human proteins remains somewhat
limited.
Clearly, more work is required to develop these mouse
models to accurately reflect human immune responses to
protein therapeutics before they can become accurate, useful,
and routine components of a Td immunogenicity screening
program.
4. Applied Td immunogenicity prediction
4.1. In silico prediction supported by subsequent
clinical data
Koren et al. [54] demonstrated a correlation between the in
silico evaluation of T helper epitope content of a protein
therapeutic and its observed immunogenicity when adminis-
tered to human subjects in a clinical trial. The therapeutic
protein of interest was a recombinant Fc fusion protein (FPX)
consisting of human germ line Fc γ fragment with two identical,
biologically active, 24-amino-acid peptides attached to the
amino terminal end of the Fc fragment. In the in silico analysis,
the carboxy terminal region of the peptide scored high for
binding to five of eight common HLAmolecules, suggesting that
this peptide had the potential to be presented by five different
HLA molecules to T cells. Moreover, the C-terminus peptides
were associated with a cluster of overlapping 9-mers that could
bind across several HLA DR alleles.
The antibody response to FPX was consistent with the high
immunogenic potential predicted in silico. A single subcutane-
ous or intravenous administration of the protein resulted in
high-affinity binding antibodies in 40% and 33% of total
individuals, respectively (Table 3). T cell-mediated recall
responses to the therapeutic protein were also assessed
in vitro for donors exhibiting a strong humoral response
in vivo. In vitro PBMC activation by the FPX peptide, and the
amino-terminal and carboxy-terminal fragments thereof, was
measured as a function of the number of IFN-γ and IL-4
spot-forming cells (SFC) in a standard ELISpot assay. The
antibody data suggested a strong T cell-driven response, which
was corroborated by the in vitro cytokine responses observed in
PBMC culture. Thus, the in silico prediction of immunogenic
T helper cell epitope(s) within the carboxy-terminal region of
the FPX peptide correlated with the in vitro T cell assays and
the in vivo antibody responses.
HLA typing confirmed the predicted binding promiscuity
of the carboxy-terminal epitope(s), as antibody-positive
subjects possessed all of the eight most common HLA alleles.
The magnitude of the immune response also appeared to
correlate with the HLA haplotype and with the best
carboxy-terminal peptide binding scores. One subject who
possessed the DRB1*0701 allele had the highest antibody
concentration as well as the highest number of IFN-γ and
IL-4 SFCs, as was predicted based on the in silico EpiMatrix
results. Another subject who had DRB1*0701 allele also
showed relatively high antibody concentration with lower,
but measurable, SFCs in vitro. Immune responses (both in
vivo antibody and in vitro T cell) to different regions of
the protein correlated with in silico predictions. The
carboxy-terminal region of the FPX peptide showed the
highest MHC binding score in the context of the DRB1*0701
allele; T cell and antibody responses to this fragment were
observed in vitro and in vivo, respectively, for individuals
possessing that allele. In contrast, the DRB1*0301 allele had
very low MHC binding scores, and patients who possessed
DRB1*0301 but not any of the other higher binding alleles
demonstrated low responses in ELISpot and no evidence of
an antibody response to the protein therapeutic. The
immunogenicity of the FPX fragments and the association
between clinical results and the HLA class II alleles were
supported in the naïve blood T cell assays in further
studies performed by Jawa et al. [40,54] the reactivity of
naïve (pre-exposure) PBMC to FPX1 was associated with
therapeutic-induced antibody responses observed in the
clinic as well as with expression of specific HLA class II
alleles that were predicted in silico to present FPX1-derived
epitopes.
This case study illustrates several important princi-
ples regarding the immunogenicity assessment of protein
therapeutics:
(i) Clinical correlation: Clinical incidence of high immuno-
genicity to FPX1 from exposed donors was retrospec-
tively associated with the in silico immunogenicity
predictions.
(ii) Promiscuous epitopes: This study demonstrated that
immunodominance was associated with clusters of
epitopes within the sequence of the FPX1 peptide.
The clustering of epitopes was associated with greater
immunogenicity as measured by a high incidence of
binding and neutralizing antibodies to FPX fusion
protein. Moreover, due to the clustering, the peptide
was more promiscuous and was able to bind across
several HLA DR alleles. This was validated when ADA
positive subjects were observed to express high-binding
alleles.
(iii) Antibody–HLA correlation: The responders with high
antibody titers expressed HLA-DR alleles that had been
predicted by the in silico algorithm to be the best
epitope binders.
(iv) In silico–T cell assay correlation: The C-terminal region
of the FPX1 peptide elicited T cell responses in PBMC from
FPX1-exposed, antibody-positive donors, supporting a
correlation between in silico prediction and observed
clinical immunogenicity.
(v) Correlation to in vitro naïve response: The predicted
immunodominant regions of the peptide were able to
elicit response from naïve PBMC with the HLA DR
predicted in silico.
4.2. Clinical link between MHC class II haplotype and
IFN-β immunogenicity [53]
A similar association between the HLA DRB1*0701 allele and
a strong antibody response to recombinant beta-interferon
was observed by Barbosa et al. The IFN-β epitopes were
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identified using a peptide library and a peptide binding assay
with B cell lines expressing this allele. Peptides were
synthesized as overlapping 17-mers covering the entire
sequence of IFN-β and combined into 10-peptide pools.
Recall responses from subjects with multiple sclerosis
receiving Type I IFN-β therapy were assessed in vitro by
measuring T cell IFN-γ ELISpots (Fig. 1). The PBMC from
antibody-positive subjects (haplotype DRB1701/DQA10201)
had high levels of IFN-γ-secreting T cells in the presence of
two of the 10 peptide pools tested, while antibody-negative
subjects showed no response. Depending on the availability
of cells, peptide pools could be de-convoluted to identify
the minimal epitope and the restricting HLA class II allele.
One limitation of such an approach is the difficulty of
defining the true immunogenic epitope, and consequently
the most relevant HLA-DR motifs, among the overlapping
peptides, as is illustrated in Fig. 1.
Stickler et al. [170] observed that DRB1*1501/DQB1*0602
haplotypes are associated with a high rate of reactivity
towards human IFN-β in the naïve T cell assay format.
Accordingly, the C-terminal IFN-β peptide 147–161 was
eluted from HLA-DR molecules after IFN-β exposure of
human DC expressing the DRB1*1501 allele (H. Kropshofer,
personal communication). Due to limitations in the number
of subjects tested, a clinical correlation with the HLA-
DRB1*1501 allele could not be detected in the Barbosa et al.
study [53]. Thus the Barbosa et al. publication nicely
illustrates some of the limitations and lessons learned in
the interpretation of in vitro studies:
(i) The overlapping peptide approach may lead to motif
truncation: The approach of using overlapping pep-
tides that are then pooled for in vitro analysis may
make it difficult to define a specific epitope or epitope
cluster, particularly if limited PBMC samples do not
accommodate de-convolution of these peptide pools
(T cell assays).
(ii) HLA skewing: Natural limitations on the number of
subjects that are exposed to the drug or HLA-association
of the disease itselfmay lead to skewed representation of
HLA alleles, thus some associations between HLA and
clinical immunogenicity may be overlooked.
(iii) Combining methods may lead to new insights: Careful
comparison of the HLA-binding and T cell assay outcomes
may uncover linkages that can better explain the results;
limiting immunogenicity screening to a single approach
may lead to misinterpretations.
5. Mitigation of T cell-dependent immunogenicity
Computer algorithms, epitope databases, and improved
statistical methods have given researchers superior tools
A)
B)
Figure 1 Association of HLA with patient immune responses. Pools of overlapping 17mers derived from IFN-β were tested in ELISpot
assays using PBMC from multiple sclerosis patients with antibody response to beta-interferon therapy (Barbosa et al., Clinical
Immunology 2006). Pools 9 and 10 stimulated significant IFN-γ responses in patients sharing a single HLA allele, DRB1*0701, thus the
minimal epitope for this allele was determined to comprise the residues shared between the two stimulatory pools. However,
immunoinformatic analysis using the EpiMatrix algorithm reveals three distinct 9-mer binding motifs for DRB1*0701 in these peptides,
none of which are fully represented in the region of overlap between the two peptide pools.
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for assessing the potential of T cell immunogenicity of
therapeutic proteins [42]. As a result, a number of different
approaches to mitigate Td immunogenicity of therapeutic
proteins are now under consideration. These approaches
include: direct modification of the therapeutic protein by
pegylation and/or glycosylation to mask “immunogenic epi-
topes”, thereby reducing recognition by the immune system;
modification of HLA class II anchor residues of immunodominant
epitopes to disrupt presentation; and application of strategies
that tolerize the immune system to the therapeutic protein.
The primary focus of this review is on methods for predicting
and measuring Td immunogenicity; hence, a thorough discus-
sion of methods for mitigating immunogenicity is beyond its
scope. However, it is important here to link our evolving ability
to identify contributors to a therapeutic protein's immunoge-
nicity with our ability to modify that feature to mitigate
unwanted immune responses. Currently, tools to predict T cell
epitopes can be applied to remove T cell epitopes. Indeed, a
method for deimmunization (protein/sequence re-engineering)
has been introduced, which involves the elimination of
predicted T cell epitopes or a reduction in the total number
of T cell epitopes. The approach has been described in detail
in a number of publications [41,171–175], and readers are
referred to those articles for details on the methodology.
Efforts to render effector T cells non-responsive through the
actions of immunosuppressive drugs or induction of Treg cells
are evolving. Finally, the ability to identify drug-induced or
drug-responsive T cells may in the future bring opportunities
to specifically deplete them.
5.1. Deimmunization
The first published attempt to deimmunize a protein
involved the introduction of alanine substitutions at the
MHC anchoring residues Y73, K74, R77, E80, and D82 of
staphylokinase, alone or in combination. These modifica-
tions to the native protein were subsequently shown to
reduce or eliminate a T cell response and clinical immuno-
genicity [176]; this was followed by a number of additional
deimmunization studies [29,41,171–175,177,178]. Ongoing
efforts include deimmunization of (1) botulinum neurotoxin
type A, (2) lysostaphin, and (3) Factor VIII [97], as well as
(4) removing T regulatory epitopes from amonoclonal antibody
(anti-DEC205) for vaccine applications. Epitope modification
has also been applied to several other therapeutic proteins
in studies performed by researchers at Biovation [179],
Epimmune [52], Genencor [180], and elsewhere, using a
range of methodologies.
Clearly, modification of the sequence of a protein can have
an impact on the secondary or tertiary structure. Thus the
utility of this approach depends on the location and extent of
amino acid changes and the impact of those changes on the
pharmacological activity of the modified protein. On a case-by-
case basis, an immunoinformatics-driven and cell-based ap-
proach to modifying protein sequences may eventually lead to
less immunogenic proteins while preserving their therapeutic
potential. Several de-immunized therapeutic proteins are in
clinical use [176]; however, in the majority of instances, the
immunogenic potential of the parent molecule was determined
by the presence of T cell epitopes and not through clinical
testing. This is the key limitation of all predictive methods, and
of course, clinical testing is the only way to “validate” any of
themethods discussed in this review. Retrospective studiesmay
be the only approach to testing the concept, but without a
head-to-head comparison of the original and deimmunized
proteins (FVIII, for example) in a clinical setting, all else will be
correlative.
5.2. Tolerization
Active interference with T cell responses to protein
therapeutics by inducing tolerance to the drug is an
approach that has garnered significant interest in the last
few years. Tolerance can be induced with non-depleting
anti-CD4 antibodies [181,182]. IVIG has also been used to
induce tolerance in solid organ transplant [183], to reduce
FVIII inhibitors [184–189], and to inhibit ADA in Pompe
patients undergoing Myozyme treatment [190]. Tolerance-
inducing protocols combining Rituxan, methotrexate and
IVIG that have been effectively applied to mitigate existing
anti-therapeutic responses in the context of life-saving
enzyme replacement therapy may provide an immediate
solution for these patients [68,190,191]. However, there are
new opportunities opening up along the developmental
pipeline to build next-generation protein therapeutics to
which patients are more tolerant. Towards this goal, De
Groot et al. have identified a set of natural, human
regulatory T cell epitopes (“Tregitopes”) present in the Fc
and Fab domains of IgG that have also been shown to induce
tolerance to co-administered proteins; these Tregitopes may
be responsible for tolerance to idiotypic epitopes. When
incubated with PBMC in vitro, Tregitopes specifically
activate CD4+ T cells, increase CD25/Foxp3 expression, and
increase expression of regulatory cytokines and chemokines
[41]. Administration of Tregitopes with protein antigens in
vivo inhibits T cell proliferation and effector cytokine
expression, and induces antigen-specific adaptive tolerance
induction. Methods for co-administering Tregitopes with
protein therapeutics are currently under development
[192–195].
6. Considerations: assessing immunogenicity of
therapeutic proteins
Given the potential impact of immunogenicity on the safety,
efficacy, and utility of a final therapeutic protein drug
product, there is increasing interest in developing ap-
proaches that will help to establish an accurate immunoge-
nicity profile for a protein therapeutic. Immunogenicity
predictions provide the greatest opportunity, and have the
greatest benefit, early during selection of a lead molecule.
Introduction of changes to the structure of a lead molecule
could be prohibitively expensive with respect to time and
resources necessary to repeat prior development and safety
studies. We suggest consideration of a multi-step approach
such as the following (Fig. 2) to evaluate the Td immunoge-
nicity potential of a therapeutic protein:
Step 1 HLA binding prediction in silico and confirmatory
assessment in vitro. A high-throughput in silico
epitope-mapping algorithm applicable across com-
mon HLA class II haplotypes could identify areas of
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putative epitope clusters within a larger protein and
allow drug candidates to be ranked in order of their
potential for immunogenicity. However, in silico
screening should never be viewed as a stand-alone
technology. The in silico results could be carried
forward by having the epitopes identified synthe-
sized for testing in an in vitro peptide-binding assay.
From this analysis, epitopes could be prioritized by
strength of binding (IC50) and by the breadth of HLA
to which they bind. To strengthen the predictive
value of in silico tools and HLA binding assays that do
not take into account antigen processing, editing, or
presentation, cell-based approaches as described
above [103] may also be applied.
Step 2 Stimulation of T cell activity in vitro. The focused set
of epitopes or portions of a larger protein identified in
Step 1 could be further assessed by in vitro human T
cell assays to study immune responsiveness to this
protein in Step 2. Knowledge gained from the in silico
analysis can be applied here to demonstrate specificity
of the response. Proliferation assays are sensitive, low
in cost, and can be designed to assess phenotype of the
responder cells. ELISpot assays and multiplex cytokine
bead arrays are moderate in cost and more sensitive;
intracellular cytokine staining methods have the
highest sensitivity but can be technically challenging
and higher in cost. It is recommended to utilize at least
two independent readouts of T cell activity to ensure a
balance between specificity and sensitivity. Results
from Step 2 should strengthen the findings of the
in silico prediction from Step 1. In addition, in vitro
screening may enable the evaluation of processing-
associated changes, such as posttranslational modi-
fications and misfolding. Where target-mediated,
agonist effects, or formulation changes of an immuno-
modulatroy therapeutic are a concern, in vitro studies
can be performed in tandem with in silico studies.
Immunogenicity assessment is an important adjunct to
preclinical studies that may facilitate the identification and
selection of the best candidates to bring towards the clinic. The
stepwise approach to preclinical Td immunogenicity assessment
proposed here progresses from higher-throughput, lower-cost
methods to narrow the search space, to lower-throughput,
higher-costmethods to screen for T cell reactivity. At this point,
a combination of these experimental results, experience
with the protein of interest, and the stage of the development
process may together prompt an effort to either proceed
into in vivo animal experiments and further development
(Fig. 2, Step 3), or perhaps to reengineer the protein to lower
immunogenicity.
7. Conclusion
In response to concerns about the potential side effects of
anti-drug immune responses, regulatory bodies such as the
FDA and the EMA have begun to request that each protein
therapeutic be accompanied by an immunogenicity risk
assessment [196,197]. For example, the recent EMA guid-
ance mentions “predictive immunogenicity” as an approach
sponsors could consider in their preclinical studies [17]. In
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Figure 2 Example roadmap for immunogenicity prediction. A potential step-wise approach to pre-clinical immunogenicity testing
is depicted here. Step 1 would consist of the in silico screening of linear sequences from multiple therapeutic candidates for T cell
epitopes and clusters. At the conclusion of Step 1, therapeutic candidates would be rated for immunogenic risk. Step 2 would be an in
vitro evaluation of immunogenicity in a series of T cell assays. This phase could include examination of antigen processing and
presentation, post-translational modifications, and different formulations. Subsequent Step 3 immunogenicity testing of therapeutic
candidates may be carried out in vivo in established “humanized” animal models such as the Hu-SCID and HLA-transgenic mice. The
culmination of this immunogenicity prediction strategy would be advancement into the drug development pipeline.
548 V. Jawa et al.
this context, the historical focus has been on measurement
of antibody responses as the read-out for immunogenicity,
supported by the obvious consequences of ADA responses on
protein therapeutic pharmacokinetics and efficacy. Td
immunogenicity assessment has been considered by many
drug developers to be an “upstream” activity, associated
with the lead candidate optimization/selection process.
Given the contribution of T cell responses to the develop-
ment of a detrimental ADA response and the emerging suite
of tools for predicting Td immunogenicity, this focus is
shifting in some instances. For example, mitigating immu-
nogenicity by modification of T cell responses, with careful
attention to potential Treg epitopes, is now mentioned in
the recently released FDA draft guidance entitled “Immu-
nogenicity Assessment for Therapeutic Protein Products”
[120].
The drug discovery and early development phases present
prime opportunities to extract the greatest value from
immunogenicity prediction tools. The cost of modifying or, in
extreme cases, abandoning drugs that are near or have reached
clinical trial stage can be quite significant [6]. Thus applying Td
immunogenicity screening earlier in the drug-development
pathway may be an important adjunct to preclinical studies in
some circumstances.
At present, drug developers are applying a range of
strategies and assays to assess and modulate humoral and/or
cell-mediated immune responses to protein therapeutic drugs
at both the preclinical and clinical phases of development.
Guidelines for standardizing immunogenicity testing of protein
therapeutics across the industry are emerging from these
activities and parallel assay standardization and validation
efforts in the vaccine discovery field. Approaches for reducing
biologic protein immunogenicity are also proceeding apace; a
number of drugs that have been de-immunized or tolerized are
now being introduced into the clinic. Additional methods, such
as tolerization using cytotoxic and immunosuppressive drugs,
are currently in use in high-risk enzyme replacement therapy
patients [66,68,191,198].
A wide range of Td immunogenicity screening methods
examining different aspects of the process by which a
protein therapeutic may trigger an immune response has
been presented here. No single method has emerged as a
definitive tool for determining whether or not a protein
therapeutic will elicit a detrimental immune response in
patients, and given the complexity of the immune system,
a singular solution may not be realistic. Rather, the field
is evolving to apply strategic combinations of multiple methods
to most closely predict and mitigate immunogenicity risk. Td
immunogenicity screening is a rapidly advancing science that
could eventually impact drug development, reducing risks to
patients and costs to industry. As more preclinical immunoge-
nicity testing is performed and clinical correlations become
available, the accuracy of preclinical immunogenicity screening
methods and their utility to industry are bound to improve.
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